Cargando…

VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies

VGF mRNA is widely expressed in areas of the nervous system known to degenerate in Amyotrophic Lateral Sclerosis (ALS), including cerebral cortex, brainstem and spinal cord. Despite certain VGF alterations are reported in animal models, little information is available with respect to the ALS patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Brancia, Carla, Noli, Barbara, Boido, Marina, Boi, Andrea, Puddu, Roberta, Borghero, Giuseppe, Marrosu, Francesco, Bongioanni, Paolo, Orrù, Sandro, Manconi, Barbara, D’Amato, Filomena, Messana, Irene, Vincenzoni, Federica, Vercelli, Alessandro, Ferri, Gian-Luca, Cocco, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063282/
https://www.ncbi.nlm.nih.gov/pubmed/27737014
http://dx.doi.org/10.1371/journal.pone.0164689
_version_ 1782459941992267776
author Brancia, Carla
Noli, Barbara
Boido, Marina
Boi, Andrea
Puddu, Roberta
Borghero, Giuseppe
Marrosu, Francesco
Bongioanni, Paolo
Orrù, Sandro
Manconi, Barbara
D’Amato, Filomena
Messana, Irene
Vincenzoni, Federica
Vercelli, Alessandro
Ferri, Gian-Luca
Cocco, Cristina
author_facet Brancia, Carla
Noli, Barbara
Boido, Marina
Boi, Andrea
Puddu, Roberta
Borghero, Giuseppe
Marrosu, Francesco
Bongioanni, Paolo
Orrù, Sandro
Manconi, Barbara
D’Amato, Filomena
Messana, Irene
Vincenzoni, Federica
Vercelli, Alessandro
Ferri, Gian-Luca
Cocco, Cristina
author_sort Brancia, Carla
collection PubMed
description VGF mRNA is widely expressed in areas of the nervous system known to degenerate in Amyotrophic Lateral Sclerosis (ALS), including cerebral cortex, brainstem and spinal cord. Despite certain VGF alterations are reported in animal models, little information is available with respect to the ALS patients. We addressed VGF peptide changes in fibroblast cell cultures and in plasma obtained from ALS patients, in parallel with spinal cord and plasma samples from the G93A-SOD1 mouse model. Antisera specific for the C-terminal end of the human and mouse VGF proteins, respectively, were used in immunohistochemistry and enzyme-linked immunosorbent assay (ELISA), while gel chromatography and HPLC/ESI-MS/MS were used to identify the VGF peptides present. Immunoreactive VGF C-terminus peptides were reduced in both fibroblast and plasma samples from ALS patients in an advanced stage of the disease. In the G93A-SOD1 mice, the same VGF peptides were also decreased in plasma in the late-symptomatic stage, while showing an earlier down-regulation in the spinal cord. In immunohistochemistry, a large number of gray matter structures were VGF C-terminus immunoreactive in control mice (including nerve terminals, axons and a few perikarya identified as motoneurons), with a striking reduction already in the pre-symptomatic stage. Through gel chromatography and spectrometry analysis, we identified one form likely to be the VGF precursor as well as peptides containing the NAPP- sequence in all tissues studied, while in the mice and fibroblasts, we revealed also AQEE- and TLQP- peptides. Taken together, selective VGF fragment depletion may participate in disease onset and/or progression of ALS.
format Online
Article
Text
id pubmed-5063282
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50632822016-11-04 VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies Brancia, Carla Noli, Barbara Boido, Marina Boi, Andrea Puddu, Roberta Borghero, Giuseppe Marrosu, Francesco Bongioanni, Paolo Orrù, Sandro Manconi, Barbara D’Amato, Filomena Messana, Irene Vincenzoni, Federica Vercelli, Alessandro Ferri, Gian-Luca Cocco, Cristina PLoS One Research Article VGF mRNA is widely expressed in areas of the nervous system known to degenerate in Amyotrophic Lateral Sclerosis (ALS), including cerebral cortex, brainstem and spinal cord. Despite certain VGF alterations are reported in animal models, little information is available with respect to the ALS patients. We addressed VGF peptide changes in fibroblast cell cultures and in plasma obtained from ALS patients, in parallel with spinal cord and plasma samples from the G93A-SOD1 mouse model. Antisera specific for the C-terminal end of the human and mouse VGF proteins, respectively, were used in immunohistochemistry and enzyme-linked immunosorbent assay (ELISA), while gel chromatography and HPLC/ESI-MS/MS were used to identify the VGF peptides present. Immunoreactive VGF C-terminus peptides were reduced in both fibroblast and plasma samples from ALS patients in an advanced stage of the disease. In the G93A-SOD1 mice, the same VGF peptides were also decreased in plasma in the late-symptomatic stage, while showing an earlier down-regulation in the spinal cord. In immunohistochemistry, a large number of gray matter structures were VGF C-terminus immunoreactive in control mice (including nerve terminals, axons and a few perikarya identified as motoneurons), with a striking reduction already in the pre-symptomatic stage. Through gel chromatography and spectrometry analysis, we identified one form likely to be the VGF precursor as well as peptides containing the NAPP- sequence in all tissues studied, while in the mice and fibroblasts, we revealed also AQEE- and TLQP- peptides. Taken together, selective VGF fragment depletion may participate in disease onset and/or progression of ALS. Public Library of Science 2016-10-13 /pmc/articles/PMC5063282/ /pubmed/27737014 http://dx.doi.org/10.1371/journal.pone.0164689 Text en © 2016 Brancia et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Brancia, Carla
Noli, Barbara
Boido, Marina
Boi, Andrea
Puddu, Roberta
Borghero, Giuseppe
Marrosu, Francesco
Bongioanni, Paolo
Orrù, Sandro
Manconi, Barbara
D’Amato, Filomena
Messana, Irene
Vincenzoni, Federica
Vercelli, Alessandro
Ferri, Gian-Luca
Cocco, Cristina
VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title_full VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title_fullStr VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title_full_unstemmed VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title_short VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
title_sort vgf protein and its c-terminal derived peptides in amyotrophic lateral sclerosis: human and animal model studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063282/
https://www.ncbi.nlm.nih.gov/pubmed/27737014
http://dx.doi.org/10.1371/journal.pone.0164689
work_keys_str_mv AT branciacarla vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT nolibarbara vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT boidomarina vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT boiandrea vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT pudduroberta vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT borgherogiuseppe vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT marrosufrancesco vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT bongioannipaolo vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT orrusandro vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT manconibarbara vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT damatofilomena vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT messanairene vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT vincenzonifederica vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT vercellialessandro vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT ferrigianluca vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies
AT coccocristina vgfproteinanditscterminalderivedpeptidesinamyotrophiclateralsclerosishumanandanimalmodelstudies